ES2653716T3 - Predicción y optimización de terapia de potasio sérico para hemoterapia de insuficiencia renal, especialmente hemodiálisis domiciliaria - Google Patents
Predicción y optimización de terapia de potasio sérico para hemoterapia de insuficiencia renal, especialmente hemodiálisis domiciliaria Download PDFInfo
- Publication number
- ES2653716T3 ES2653716T3 ES14755746.6T ES14755746T ES2653716T3 ES 2653716 T3 ES2653716 T3 ES 2653716T3 ES 14755746 T ES14755746 T ES 14755746T ES 2653716 T3 ES2653716 T3 ES 2653716T3
- Authority
- ES
- Spain
- Prior art keywords
- patient
- potassium
- hemodialysis
- dialysis
- dialysate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000011591 potassium Substances 0.000 title claims abstract description 429
- 229910052700 potassium Inorganic materials 0.000 title claims abstract description 429
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title claims abstract description 428
- 238000001631 haemodialysis Methods 0.000 title claims abstract description 366
- 230000000322 hemodialysis Effects 0.000 title claims abstract description 366
- 210000002966 serum Anatomy 0.000 title claims abstract description 189
- 238000002560 therapeutic procedure Methods 0.000 title claims description 153
- 238000005457 optimization Methods 0.000 title description 59
- 208000001647 Renal Insufficiency Diseases 0.000 title description 26
- 201000006370 kidney failure Diseases 0.000 title description 26
- 238000011282 treatment Methods 0.000 claims abstract description 359
- 238000000502 dialysis Methods 0.000 claims abstract description 242
- 238000000034 method Methods 0.000 claims abstract description 150
- 230000036470 plasma concentration Effects 0.000 claims abstract description 52
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 32
- 230000037396 body weight Effects 0.000 claims abstract description 25
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 64
- 239000004202 carbamide Substances 0.000 claims description 64
- 210000004369 blood Anatomy 0.000 claims description 33
- 239000008280 blood Substances 0.000 claims description 33
- 230000017531 blood circulation Effects 0.000 claims description 31
- 238000012546 transfer Methods 0.000 claims description 13
- 238000005070 sampling Methods 0.000 claims description 12
- 238000005534 hematocrit Methods 0.000 claims description 10
- 238000007459 endoscopic retrograde cholangiopancreatography Methods 0.000 abstract description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 245
- 229910052698 phosphorus Inorganic materials 0.000 description 245
- 239000011574 phosphorus Substances 0.000 description 245
- 229910019142 PO4 Inorganic materials 0.000 description 75
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 75
- 239000010452 phosphate Substances 0.000 description 75
- 230000001225 therapeutic effect Effects 0.000 description 47
- 230000000694 effects Effects 0.000 description 43
- 239000012530 fluid Substances 0.000 description 39
- 238000004364 calculation method Methods 0.000 description 24
- 238000005259 measurement Methods 0.000 description 23
- 230000008030 elimination Effects 0.000 description 21
- 238000003379 elimination reaction Methods 0.000 description 21
- 208000029078 coronary artery disease Diseases 0.000 description 17
- 235000012631 food intake Nutrition 0.000 description 16
- 230000037406 food intake Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 239000011230 binding agent Substances 0.000 description 15
- 230000003834 intracellular effect Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 230000008901 benefit Effects 0.000 description 13
- 238000004088 simulation Methods 0.000 description 13
- 238000011269 treatment regimen Methods 0.000 description 13
- 230000009467 reduction Effects 0.000 description 12
- 230000032258 transport Effects 0.000 description 12
- 238000009526 daily hemodialysis Methods 0.000 description 11
- 230000003442 weekly effect Effects 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000002615 hemofiltration Methods 0.000 description 9
- 230000015654 memory Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000009534 blood test Methods 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 208000020832 chronic kidney disease Diseases 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000011277 treatment modality Methods 0.000 description 6
- 210000000476 body water Anatomy 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 210000003722 extracellular fluid Anatomy 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- -1 P2-M Chemical compound 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 208000028208 end stage renal disease Diseases 0.000 description 4
- 201000000523 end stage renal failure Diseases 0.000 description 4
- 238000011369 optimal treatment Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000007485 conventional hemodialysis Methods 0.000 description 3
- 235000018823 dietary intake Nutrition 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000002977 intracellular fluid Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 101000951145 Homo sapiens Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Proteins 0.000 description 2
- 208000002682 Hyperkalemia Diseases 0.000 description 2
- 208000019025 Hypokalemia Diseases 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 102100038014 Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Human genes 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000005055 memory storage Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 238000009536 nocturnal hemodialysis Methods 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- WGNAKZGUSRVWRH-UHFFFAOYSA-N p-cresol sulfate Chemical compound CC1=CC=C(OS(O)(=O)=O)C=C1 WGNAKZGUSRVWRH-UHFFFAOYSA-N 0.000 description 2
- 208000024896 potassium deficiency disease Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012959 renal replacement therapy Methods 0.000 description 2
- 238000011300 routine therapy Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101150091187 SLC8B1 gene Proteins 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003017 phosphorus Chemical class 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1613—Profiling or modelling of patient or predicted treatment evolution or outcome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3403—Regulation parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3607—Regulation parameters
- A61M1/3609—Physical characteristics of the blood, e.g. haematocrit, urea
- A61M1/361—Physical characteristics of the blood, e.g. haematocrit, urea before treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3607—Regulation parameters
- A61M1/3609—Physical characteristics of the blood, e.g. haematocrit, urea
- A61M1/3612—Physical characteristics of the blood, e.g. haematocrit, urea after treatment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Emergency Medicine (AREA)
- External Artificial Organs (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/969,162 US9132219B2 (en) | 2010-04-16 | 2013-08-16 | Therapy prediction and optimization of serum potassium for renal failure blood therapy, especially home hemodialysis |
| US201313969162 | 2013-08-16 | ||
| PCT/US2014/050383 WO2015026542A1 (en) | 2013-08-16 | 2014-08-08 | Therapy prediction and optimization of serum potassium for renal failure blood therapy, especially home hemodialysis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2653716T3 true ES2653716T3 (es) | 2018-02-08 |
Family
ID=52484047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14755746.6T Active ES2653716T3 (es) | 2013-08-16 | 2014-08-08 | Predicción y optimización de terapia de potasio sérico para hemoterapia de insuficiencia renal, especialmente hemodiálisis domiciliaria |
| ES17173110T Active ES2717130T3 (es) | 2013-08-16 | 2014-08-08 | Optimización de terapia de potasio sérico para hemoterapia de insuficiencia renal, especialmente hemodiálisis domiciliaria |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17173110T Active ES2717130T3 (es) | 2013-08-16 | 2014-08-08 | Optimización de terapia de potasio sérico para hemoterapia de insuficiencia renal, especialmente hemodiálisis domiciliaria |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP3033704B1 (enExample) |
| JP (1) | JP6477704B2 (enExample) |
| AU (1) | AU2014309285A1 (enExample) |
| CA (1) | CA2919223A1 (enExample) |
| ES (2) | ES2653716T3 (enExample) |
| MX (1) | MX361881B (enExample) |
| WO (1) | WO2015026542A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018012592A (es) * | 2016-04-15 | 2019-05-30 | Becton Dickinson Co | Dispositivo medico con lengüeta antirrotacion de empuje. |
| JP6716428B2 (ja) * | 2016-11-11 | 2020-07-01 | 日機装株式会社 | 血液浄化治療支援システム |
| JP6997582B2 (ja) * | 2017-10-17 | 2022-01-17 | 日機装株式会社 | 血液浄化装置 |
| JP6914803B2 (ja) * | 2017-10-17 | 2021-08-04 | 日機装株式会社 | 血液浄化装置 |
| DE102017130548A1 (de) * | 2017-12-19 | 2019-06-19 | Fresenius Medical Care Deutschland Gmbh | Verfahren und Vorrichtungen zum Festlegen eines Behandlungsregimes zum Verändern von Behandlungsparametern beim Dialysieren eines Patienten |
| JP2019212249A (ja) * | 2018-06-10 | 2019-12-12 | 大 益満 | プログラム及び情報処理システム |
| CN113574607A (zh) * | 2019-03-11 | 2021-10-29 | 甘布罗伦迪亚股份公司 | 估计透析患者体内物质的生成率 |
| CA3156801A1 (en) | 2019-10-04 | 2021-04-08 | Fresenius Medical Care Holdings, Inc. | Techniques for determining patient blood characteristics during a dialysis process |
| CN117715667A (zh) * | 2021-07-26 | 2024-03-15 | 株式会社Jms | 透析条件设定辅助装置和程序 |
| WO2023053266A1 (ja) * | 2021-09-29 | 2023-04-06 | 国立大学法人静岡大学 | 透析情報提供装置及び透析情報提供プログラム |
| EP4678200A4 (en) * | 2023-05-25 | 2026-07-08 | Physiologas Tech Inc | HEMODIALYSIS TREATMENT SUPPORT SYSTEM |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10339342B3 (de) * | 2003-08-25 | 2005-01-20 | Fresenius Medical Care Deutschland Gmbh | Blutbehandlungsvorrichtung |
| JP4548349B2 (ja) * | 2006-01-20 | 2010-09-22 | 株式会社ジェイ・エム・エス | 血液透析装置 |
| US9028691B2 (en) | 2007-02-27 | 2015-05-12 | Deka Products Limited Partnership | Blood circuit assembly for a hemodialysis system |
| US8042563B2 (en) | 2007-02-27 | 2011-10-25 | Deka Products Limited Partnership | Cassette system integrated apparatus |
| US8888470B2 (en) | 2007-02-27 | 2014-11-18 | Deka Products Limited Partnership | Pumping cassette |
| US8393690B2 (en) | 2007-02-27 | 2013-03-12 | Deka Products Limited Partnership | Enclosure for a portable hemodialysis system |
| US8562834B2 (en) | 2007-02-27 | 2013-10-22 | Deka Products Limited Partnership | Modular assembly for a portable hemodialysis system |
| US20090107335A1 (en) | 2007-02-27 | 2009-04-30 | Deka Products Limited Partnership | Air trap for a medical infusion device |
| US8062513B2 (en) | 2008-07-09 | 2011-11-22 | Baxter International Inc. | Dialysis system and machine having therapy prescription recall |
| US9514283B2 (en) | 2008-07-09 | 2016-12-06 | Baxter International Inc. | Dialysis system having inventory management including online dextrose mixing |
| US7981281B2 (en) | 2008-07-09 | 2011-07-19 | Baxter International, Inc. | Dialysis system having regimen generation methodology |
| US8168063B2 (en) | 2008-07-09 | 2012-05-01 | Baxter International Inc. | Dialysis system having filtering method for determining therapy prescriptions |
| US8057679B2 (en) | 2008-07-09 | 2011-11-15 | Baxter International Inc. | Dialysis system having trending and alert generation |
| JP5747072B2 (ja) * | 2010-04-16 | 2015-07-08 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 腎不全血液療法、特に、在宅血液透析のための療法の予測および最適化 |
| US9132219B2 (en) * | 2010-04-16 | 2015-09-15 | Baxter International Inc. | Therapy prediction and optimization of serum potassium for renal failure blood therapy, especially home hemodialysis |
-
2014
- 2014-08-08 MX MX2016002083A patent/MX361881B/es active IP Right Grant
- 2014-08-08 EP EP14755746.6A patent/EP3033704B1/en not_active Not-in-force
- 2014-08-08 ES ES14755746.6T patent/ES2653716T3/es active Active
- 2014-08-08 JP JP2016534762A patent/JP6477704B2/ja active Active
- 2014-08-08 EP EP17173110.2A patent/EP3229159B1/en not_active Not-in-force
- 2014-08-08 WO PCT/US2014/050383 patent/WO2015026542A1/en not_active Ceased
- 2014-08-08 ES ES17173110T patent/ES2717130T3/es active Active
- 2014-08-08 AU AU2014309285A patent/AU2014309285A1/en not_active Abandoned
- 2014-08-08 CA CA2919223A patent/CA2919223A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015026542A1 (en) | 2015-02-26 |
| MX2016002083A (es) | 2016-06-23 |
| ES2717130T3 (es) | 2019-06-19 |
| MX361881B (es) | 2018-12-18 |
| EP3229159A1 (en) | 2017-10-11 |
| AU2014309285A1 (en) | 2016-01-28 |
| EP3033704B1 (en) | 2017-10-04 |
| JP2016535644A (ja) | 2016-11-17 |
| EP3229159B1 (en) | 2018-12-26 |
| EP3033704A1 (en) | 2016-06-22 |
| JP6477704B2 (ja) | 2019-03-06 |
| CA2919223A1 (en) | 2015-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2717130T3 (es) | Optimización de terapia de potasio sérico para hemoterapia de insuficiencia renal, especialmente hemodiálisis domiciliaria | |
| ES2501715T3 (es) | Predicción y optimización de terapia para la hemoterapia de la insuficiencia renal, especialmente de la hemodiálisis domiciliaria | |
| US9132219B2 (en) | Therapy prediction and optimization of serum potassium for renal failure blood therapy, especially home hemodialysis | |
| Himmelfarb et al. | Urea volume of distribution exceeds total body water in patients with acute renal failure | |
| Gotch et al. | Whither goest kt/v? | |
| Bosticardo et al. | Optimizing the dialysate calcium concentration in bicarbonate haemodialysis | |
| Daugirdas et al. | Effect of treatment spacing and frequency on three measures of equivalent clearance, including standard Kt/V | |
| Debowska et al. | Bimodal dialysis: theoretical and computational investigations of adequacy indices for combined use of peritoneal dialysis and hemodialysis | |
| IT202000026209A1 (it) | Apparatus for extracorporeal treatment of blood and process of calculating set flow rates in a medical apparatus for extracorporeal treatment of blood | |
| Marsenic et al. | Application of individualized Bayesian urea kinetic modeling to pediatric hemodialysis | |
| Al Mamun et al. | Clinical application of computer-aided diagnostic system for harmonious introduction of complementary dialysis therapy |